TPP1 is a lysosomal serine protease with tripeptidyl-peptidase I activity.
It may act as a non-specific lysosomal peptidase which releases an N-terminal tripeptide from the breakdown products produced by lysosomal proteinases.
Requires substrates with an unsubstituted N-terminus.
TPP1 is detected in lysosomes and melanosomes in all tissues but it is highest in the heart and placenta.
TPP1 is activated by autocatalytic proteolytic processing upon acidification within lysosomes.
Defects in TPP1 cause classical late-infantile neuronal ceroid lipofuscinosis (LINCL) which is also known as ceroid lipofuscinosis 2 (CLN2).
It is a fatal childhood neurodegenerative disease characterised by progressive visual and mental deterioration, motor disturbance, epilepsy and behavioral changes.
Applications:Suitable for use in ELISA and Western Blot.
Other applications not tested.
Recommended Dilution:ELISA (Peptide): 1:4000Western Blot: 0.3-1ug/mlOptimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4°C for short-term only.
Aliquot to avoid repeated freezing and thawing.
Store at -20°C.
Aliquots are stable for 12 months after receipt.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
Size：100ug
Host：goat
Source Antibody：human
Grade：Affinity Purified
Purity：Purified by affinity chromatography.
Form：Supplied as a liquid in Tris saline, 0.02% sodium azide, pH7.3, 0.5% BSA.
Specificity：Recognizes human CLN2/TPP1.
Isotype：IgG
Calc Applications Abbrev：E WB
Calc Crossreactivity：Hu
Immunogen：Synthetic peptide corresponding to C-TPSVIRKRYNLTSQD from the internal region of human CLN2/TPP1 (NP_000382.3). Species sequence homology: bovine, canine
